Search

eye Insights TM Issue 3 focuses on the Boston KPro, specifically on how to manage complications associated with implantation, postoperative treatment guidelines, and new clinical innovations. Eye Insights is a clinical newsletter published by Massachusetts Eye and Ear and Massachusetts General...

Many inherited diseases are caused by mutations in a single gene (Mendelian disorder), and detection of the responsible mutation can predict development of the disease with relatively high accuracy. If your clinical findings suggest the presence of an inherited eye disease, such as those described...

Herpes zoster ophthalmicus (HZO) is reactivation of a varicella zoster virus infection (shingles) involving the eye. In the acute phase, patients present with a dermatomal forehead rash and severe pain around the infected area. Inflammation of anterior segment tissues and, less commonly, posterior...

Dear Colleagues, In this issue of eye Insights, we highlight two treatments for the management of strabismus: botulinum toxin and adjustable sutures. We include indications for their use, techniques to incorporate them into practice, and outcomes. A list of peer-reviewed journal articles is included...

Botulinum toxin (BT) for the management of strabismus was approved by the FDA in 1989 based on work by pediatric ophthalmologist Alan B. Scott, MD. BT can be the first-line treatment for certain forms of strabismus. Indications Acute comitant esotropia in children: BT can be injected to both medial...

Standard strabismus surgery involves altering the position or length of the extraocular muscles to improve ocular alignment. The muscle is reattached to the globe at a set position. The adjustable suture technique was introduced to refine the result immediately after surgery in both adults and...

In the past decade, several new IOL technologies have become available: extended depth of focus (EDOF), multifocal (MFIOL), and light adjustable lenses (LAL). EDOF IOLs offer a range of vision from distance to intermediate. MFIOLs, which are now available as trifocals, offer 3 steps of vision...

Until the approval of Luxturna®, there were no definitive treatments for any IRDs. Today, with the success of Luxturna®, preliminary results from therapies currently under investigation, and an expanding therapeutic toolkit, we have good reason for optimism. We envision a future in which gene...